A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer. Materials and Methods Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study. Inclusion criteria included no prior systemic chemotherapy or radiation therapy, at least one radiographically documented and measurable tumor lesion, and adequate patient organ functions. The patients received 1,000 mg/m2 gemcitabine intravenously on days 1, 8 and 15, and 830 mg/m2of oral capecitabine twice a day on days 1-21 of a 28-day cycle. Results Fifty patients with a median age of 53 years (range, 39 to 76 years) were enrolled in the study. The median follow-up was 10.0 months. The objective response rate of the 50 patients was 48.0% (95%CI, 22.5 to 57.1%). The median time to progression and overall survival were 6.5 months (95% CI,2.3 to 8.7 months) and 10.0 months (95% CI, 5.7 to 16.7 months), respectively. Grade 3-4 toxicities associated with chemotherapy included neutropenia (22%), anemia (8%), thrombocytopenia (6%),and hand-foot syndrome (10%). Conclusion Combination chemotherapy using gemcitabine and capecitabine was well tolerated and demonstrated promising efficacy in the treatment of advanced pancreatic cancer.
Abstract
Purpose The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer. Materials and Methods Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study. Inclusion criteria included no prior systemic chemotherapy or radiation therapy, at least one radiographically documented and measurable tumor lesion, and adequate patient organ functions. The patients received 1,000 mg/m2 gemcitabine intravenously on days 1, 8 and 15, and 830 mg/m2of oral capecitabine twice a day on days 1-21 of a 28-day cycle. Results Fifty patients with a median age of 53 years (range, 39 to 76 years) were enrolled in the study. The median follow-up was 10.0 months. The objective response rate of the 50 patients was 48.0% (95%CI, 22.5 to 57.1%). The median time to progression and overall survival were 6.5 months (95% CI,2.3 to 8.7 months) and 10.0 months (95% CI, 5.7 to 16.7 months), respectively. Grade 3-4 toxicities associated with chemotherapy included neutropenia (22%), anemia (8%), thrombocytopenia (6%),and hand-foot syndrome (10%). Conclusion Combination chemotherapy using gemcitabine and capecitabine was well tolerated and demonstrated promising efficacy in the treatment of advanced pancreatic cancer.
참고문헌 (24)
- Koorstra JB, "Pancreatic carcinogenesis", Pancreatology, 8, pp.110~125 (2008)
- Storniolo AM, "An investigational new drug treatment program for patients with gemcitabine : results for over 3000 patients with pancreatic carcinoma", Cancer, 85, pp.1261~1268 (1999)
- Cullinan S, "Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin", Cancer, 65, pp.2207~2212 (1990)
- Burris HA 3rd, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial", J Clin Oncol, 15, pp.2403~2413 (1997)
- Barhoumi M, "Locally advanced unresectable pancreatic cancer : induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone : definitive results of the 2000-2001 FFCD", SFRO phase III trial, 2011, pp.15, 182~191
- Oettle H, "A phase II trial of gemcitabine in combination with 5-fluorouracil(24-hour)and folinic acid in patients with chemonaive advanced pancreatic cancer", Ann Oncol, 11, pp.1267~1272 (2000)
- Matano E, "Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer : a clinical benefit-oriented phase II study", Br J Cancer, 82, pp.1772~1775 (2000)
- Cartwright TH, "Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer", J Clin Oncol, 20, pp.160~164 (2002)
- Stathopoulos GP, "Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine : an intergroup, multicenter, phase II study", Ann Oncol, 15, pp.224~229 (2004)
- Hess V, "Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma : a phase I", II trial, 2003, pp.21, 66~68
- Scheithauer W, "Biweekly highdose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma : a randomized phase II trial", Ann Oncol, 14, pp.97~104 (2003)
- Schilsky RL, "Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer", J Clin Oncol, 20, pp.582~587 (2002)
- Cunningham D, "Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer", J Clin Oncol, 27, pp.5513~5518 (2009)
- Park BB, "A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma", Cancer Chemother Pharmacol, 60, pp.489~494 (2007)
- Carmichael J, "Phase II study of gemcitabine in patients with advanced pancreatic cancer", Br J Cancer, 73, pp.101~105 (1996)
- Rocha Lima CM, "Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate", J Clin Oncol, 22, pp.3776~3783 (2004)
- Louvet C, "Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial", J Clin Oncol, 23, pp.3509~3516 (2005)
- Abou-Alfa GK, "Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer", J Clin Oncol, 24, pp.4441~4447 (2006)
- Oettle H, "A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer", Ann Oncol, 16, pp.1639~1645 (2005)
- Van Cutsem E, "Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer", J Clin Oncol, 22, pp.1430~1438 (2004)
- Herrmann R, "Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer : a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group", J Clin Oncol, 25, pp.2212~2217 (2007)
- Harsha HC, "Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy", J Proteome Res, 7, pp.4651~4658 (2008)
- Moore MJ, "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol, 25, pp.1960~1966 (2007)
- Philip PA, "Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment", J Clin Oncol, 27, pp.5660~5669 (2009)